Mini-Monoka® is the gold standard for canalicular repair. It consists of a 40 mm silicone tube with a plug-like fixation head. Its special design effectively treat canalicular lacerations involving the external 2/3 of one canaliculus.

FCI Bioceramic orbital implants have become the new standard in orbital implant material. These implants have an improved vascularization structure over other existing alternatives, allowing for quick fibrovascularization.

Ritleng®+ is FCI latest autostable bicanalicular nasolacrimal intubation consisting of a silicone tube connected at each extremity to a PEEK thread guide to reduce operating time and trauma for the patients. The intubation is self-retaining thanks to two wider silicone portions on the silicone tube. The surgical procedure is similar to the conventional Ritleng® lacrimal intubation and involves the use of Ritleng® instruments.

Precivia® simplifies intravitreal injections by making the procedure faster and more predictable. Its unique design presents a guide tube accurately oriented to ensure a fixed injection angle of 28°, a fixed distance at 3.5 mm from the limbus, and a controlled depth.

The StopLoss™ Jones tube introducer set enables the surgeon to choose the most appropriate diameter and length of the StopLoss™ Jones tube prior to tube insertion.

The wrapping technique consists to wrap a bioceramic orbital implant with a resorbable mesh. This procedure facilitates both placement of the orbital implant into the eye socket and also muscles suturing. Additionally, the wrapping technique takes a few minutes to perform and avoid the use of donor material.

OCULID® implants are indicated for the treatment of the functional defects of lagophthalmos resulting from facial paralysis. They conform to the surface curvature of the eye, offering superior cosmesis and aesthetic satisfaction among patients. Additionally, they feature a sleek surface, anatomically friendly curvature with tapered edges, and smoothly rounded corners.

Preloaded Monoka (Lacrijet) and congenital nasolacrimal duct obstruction: Initial results

FCI is excited to share the results of a recent study conducted by Bruno Fayet, MD (Paris, France), Jean-Marc Ruban, MD (Lyon, France) and William Katowitz, MD (Philadelphia, USA) on LacriJet®.

This article was published last May, in the ‘French Journal of Ophthalmology’ and highlights the performance of LacriJet® for the management of congenital nasolacrimal duct obstruction (CNLDO).

FCI Ophthalmics Cataract Catalog